1. Scrip
  2. >>Business
  3. >>Earnings

Catalyst's Firdapse Expansion To Myasthenia Gravis In Doubt, LEMS Launch Disrupted By COVID-19

 
• By Jessica Merrill
Wooden roadblock in nature
Catalyst's indication expansion strategy hits a roadblock • Source: Shutterstock

Catalyst Pharmaceuticals, Inc.'s plan to expand Firdapse (amifampridine phosphate) to a broader range of inherited neuromuscular disorders has stalled for a second time with a Phase III clinical trial failure in patients with anti-MuSK antibody-positive myasthenia gravis, following a failed clinical trial in another rare neuromuscular condition last year.

The company announced the latest study failure with its second quarter financial results on 11 August. It also reported the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.